MetaCap

Cingulate (CING) vs Coya Therapeutics (COYA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cingulate (CING) has outperformed Coya Therapeutics (COYA) over the past year, gaining 27.8% versus a loss of 50.7%. Coya Therapeutics is the larger company by market cap ($69.2 million vs $67.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CING+27.76%COYA-50.67%
+244%+89%-67%
Nov 21, 20251 yearNov 20, 2026
CING-98.12%COYA-37.74%
+124%+7%-110%
Dec 26, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CING versus COYA key metrics
MetricCINGCOYA
Share price$4.51$2.95
Market cap$67.48M$69.20M
1-day change-14.26%-1.01%
YTD return+3.92%-49.14%
1-year return+27.76%-50.67%
EPS (TTM)$-2.67$-1.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$7.95M
Revenue growth (YoY)—+123.57%
Net income (latest FY)$-22.45M$-21.23M
Operating margin—-283.87%
Net margin—-267.14%
52-week high$11.89$6.62
52-week low$3.16$2.72
Distance from 52-week high-62.07%-55.44%
Analyst consensusnonestrong_buy
Avg. price target upside+370.07%+415.59%
Average volume178.82K149.18K
Shares outstanding14.96M23.46M
Employees148
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CING has outperformed COYA by 78.4 percentage points over the past year.

About Cingulate

CING stock →

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

About Coya Therapeutics

COYA stock →

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

CING vs COYA FAQ

Which is bigger, Cingulate or Coya Therapeutics?

Coya Therapeutics (COYA) is larger, with a market capitalization of $69.20M compared with $67.48M for Cingulate (CING).

Which stock has performed better over the past year, CING or COYA?

CING returned +27.76% over the past 12 months, compared with -50.67% for COYA (price return, excluding dividends). Past performance does not predict future results.

Are Cingulate and Coya Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons